Correction to: Scientific Reports https://doi.org/10.1038/s41598-020-74187-6, published online 14 October 2020


The original version of this Article contained an error in Figure 2 where the average spot for “CD11c+ DC + Epoxomicin” was incorrect in panel (d). The original Figure 2 and accompanying legend appear below.

Figure 2
figure 2

Comparison of the SART293–101-specific CTL induction and its function between short (SART293–101) and long (TAS0314) peptides. (a) Comparison of the frequency of SART293–101-specific CTLs. HLA-*A2402 KI mice (n = 10/group) were vaccinated with TAS0314 (100 µg) or SART293–101 peptide (21 µg, equivalent molar mass to TAS0314). One week after the last immunization, SART293–101-specific IFN-γ production from the lymphocytes of each mouse was evaluated with an IFN-γ ELISPOT assay. Data represent the mean ± standard error (n = 10). (b) Cytokine multi-functionality of SART293–101-specific CTLs. Peripheral blood mononuclear cells were prepared from immunized mice (n = 10/group) and stimulated overnight with SART293–101 peptide (10 μM). The production of IFN-γ, TNF-α, and IL-2 was analyzed in CD90.2+/CD8+ cells. (c) Comparison of the frequency of SART293–101-specific CTLs in the prime-boost vaccination condition. HLA-*A2402 KI mice (n = 5/group) were vaccinated three times at weekly intervals with TAS0314 (100 µg) or SART293–101 peptide (21 µg). One hundred and forty-eight days after the last immunization, all mice were immunized with SART293–101 peptide (21 µg). Data represent the mean ± standard error (n = 5). (d) Evaluation of the antigen presentation of TAS0314. SART3302–310 epitope-specific CTLs were cultured with TAS0314-pulsed CD3+ T cells, CD11c+ DCs, or epoxomicin-treated CD11c+ DCs. Data represent the mean ± standard deviation (n = 4). *p < 0.05 using a two-tailed Student’s t test.

Full size image

The original Article has been corrected.